Genetics of pain and analgesics – current insights and future directions

Pain perception and chronic pain susceptibility exhibit substantial interindividual variability, a significant portion of which is influenced by genetic factors. This mini–review summarizes the current understanding of pain genetics, covering early candidate gene discoveries, recent genome–wide association studies (GWAS), pharmacogenetic insights, and emerging clinical applications. Key pain–related genes such as OPRM1, COMT, and KCNJ6 have been implicated in modulating pain sensitivity and analgesic responses. Early candidate gene studies identified polymorphisms in neurotransmitter, inflammatory, and neuroplasticity–related genes associated with pain phenotypes, although many findings had limited replication. GWAS in large cohorts have since revealed dozens of risk loci contributing to chronic pain conditions, highlighting pathways in neural development, immune modulation, and opioid signaling. Pharmacogenetic research has unraveled how genetic variability in drug–metabolizing enzymes and targets (e.g., CYP2D6 and the μ–opioid receptor) affects individual responses to analgesics, paving the way for personalized pain management. We also discuss clinical decision algorithms incorporating genetic information to guide opioid prescribing and the challenges in translating genetic findings into routine care. In summary, the genetics of pain is a rapidly advancing field with promise to improve understanding of pain mechanisms and to enhance pain management through precision medicine, though further research is needed to fully realize personalized pain therapeutics.